European Journal of Heart Failure Supplements This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Residual cardiovascular risk
(Source: European Journal of Heart Failure Supplements)
Source: European Journal of Heart Failure Supplements - April 11, 2016 Category: Cardiology Authors: Ferrari, R., Catapano, A. L. Tags: Editorial Source Type: research

Case Reports
Discussion Heart rate is a well-known sign of clinical prognosis patient with congestive heart failure with cardiogenic shock. This case supported the fact that Ivabradine, a specific inhibitor of If channel, which aim to decreasing heart rate and oxygen demand in congestive heart failure condition with cardiogenc shock. (Source: European Journal of Heart Failure Supplements)
Source: European Journal of Heart Failure Supplements - April 7, 2016 Category: Cardiology Authors: Widya, A., Vitriyaturrida, , Anjarwani, S., Jalaludinsyah, A., Nugraha, T., Widyawati, D. G., Rina, K., Hindoro, E., Pratama, V., Permana, B. A., Purnawan, I., Pranata, R., Fonda, G., Supriadi, E., Nadia, I., Alkatiri, A. A., Firman, D., Adi, G., Widyant Tags: Abstracts Source Type: research

Original Research
Conclusion The prevalence of left ventricular geometric alteration and diastolic dysfunction is high among hypertensive patients at Kubu Village. Our study also found that majority of patient with known history of long-standing hypertension also have evidence of left ventricular geometry alteration. This result warrants the need for improved achievement of blood pressure goals alongside with aggressive screening for end organ damage in hypertensive patients, especially at rural area. (Source: European Journal of Heart Failure Supplements)
Source: European Journal of Heart Failure Supplements - April 7, 2016 Category: Cardiology Authors: Yasmin, A., Widiana, R., Aryadi, A., Porotuo, Y. A., Hersunarti, N., Dharma, S., Soesanto, A. M., Widya, A., Ubaidillah, N., Vittryaturida, , Siwi, K., Failasufi, M., Ramadhan, F., Wulandari, H., Waranugraha, Y., Putri, D. H., Sargowo, D., Suwirya, A. P. Tags: Abstracts Source Type: research

Young Investigator Award
Conclusion The result shows Ganoderma lucidum polysaccharide peptides has the same efficacy to reduced the level of CECs in both of groups but not in EPCs which are biomarkers of repair with therapeutic potential both in stable angina and high risk group, because EPCs level is decreasing too. A reduction of EPC levels correlated with risk factor of coronary artery disease that still unclear. The level of total cholesterol does not show significant differences between pre test and post test. (Source: European Journal of Heart Failure Supplements)
Source: European Journal of Heart Failure Supplements - April 7, 2016 Category: Cardiology Authors: Satria, A., Siwi, K., Widya, A., Vittryaturida, , Ubaidillah, N., Failasufi, M., Ramadhan, F., Wulandari, H., Waranugraha, Y., Putri, D. H., Sargowo, D., Husink, A., Soesanto, A. M., Lilyasari, O., Adji, A. B., Artiko, E. N., Romdoni, R., Aritonang, F. A Tags: Abstracts Source Type: research

Abstracts of the 25th Annual Scientific Meeting of Indonesian Heart Association 2015 (25th ASMIHA) Jakarta, Indonesia, April 15-17, 2016
(Source: European Journal of Heart Failure Supplements)
Source: European Journal of Heart Failure Supplements - April 7, 2016 Category: Cardiology Tags: Abstracts Source Type: research

Shorter (=12 months) dual antiplatelet therapy after second-generation drug-eluting stents implantation: a meta-analysis of randomized controlled trials
Optimal duration of dual antiplatelet therapy (DAPT) after second-generation drug-eluting stent (DES) remains unknown. We performed a meta-analysis to evaluate the efficacy and safety of ≤6-month vs. ≥12-month DAPT after implantation of second-generation DES in order to estimate the optimal duration of DAPT. We conducted a literature search for randomized control trials (RCTs) in popular databases including EMBASE, PubMed, the Cochrane Library, and Scopus. Independent investigators abstracted the data on outcomes, characteristics, and qualities of trials included. A fixed-effect model was adopted to pool odds ratios ...
Source: European Journal of Heart Failure Supplements - February 29, 2016 Category: Cardiology Authors: Huang, H., Li, Y., Sun, M. Tags: Articles Source Type: research

Plasma IgG antibody against cytomegalovirus but not herpes simplex virus is associated with recurrence of atrial fibrillation after catheter ablation
This study sought to determine the role of viral pathogens, herpes simplex virus (HSV)-1, HSV-2, and cytomegalovirus (CMV), in AF recurrence after radiofrequency catheter ablation in a strictly selected patient population. A total of 4148 patients undergoing AF catheter ablation were screened for structural heart diseases and known risk factors for AF, and the resultant 103 patients (74 paroxysmal and 29 persistent) were recruited. Pre-ablation clinical and laboratory data and viral-specific IgG antibody levels were compared with those in 72 healthy control subjects. Plasma concentrations of the antibodies were all signifi...
Source: European Journal of Heart Failure Supplements - February 29, 2016 Category: Cardiology Authors: Liu, S., Liu, N., Ruan, Y., Li, X., Wen, D., Chen, L., Guo, X., Guo, L., Jiang, C., Long, D., Yu, R., Tang, R., Sang, C., Bai, Y., Zhang, T., Bai, R., Du, X., Dong, J., Ma, X., Ma, C. Tags: Articles Source Type: research

Effect of verapamil in the treatment of type 2 long QT syndrome is not a dose-dependent pattern: a study from bedside to bench, and back
This study aimed to investigate the efficacy and mechanism of a calcium channel blocker, verapamil, to improve clinical manifestations in LQT2. A 42-year-old woman with a LQT2 phenotype underwent candidate gene screening. Therapeutic effects of verapamil were evaluated by QT-interval measurement and shock count of implantable cardioverter-defibrillator. The electrophysiological effect of verapamil was assessed in a LQT2 model using rabbit ventricular wedge preparations. Direct sequencing of her DNA revealed a heterozygous D609N mutation in KCNH2. Acute administration of intravenous verapamil (10 mg/h) successfully abolishe...
Source: European Journal of Heart Failure Supplements - February 29, 2016 Category: Cardiology Authors: Liu, Y., Xue, Y., Wu, S., Duan, J., Lin, L., Wang, L., Zhang, C., Liu, N., Bai, R. Tags: Articles Source Type: research

Effect of intravenous L-carnitine in Chinese patients with chronic heart failure
Chronic heart failure (CHF) may be associated with an energy deficit in cardiac muscle. As levo-carnitine (LC) is involved in the production of myocardial energy, it is hypothesized that LC supplementation may ameliorate CHF symptoms. This multicentre, randomized, double-blind, and placebo-controlled study included 265 patients with CHF. Patients were randomized to receive either LC or placebo, twice a day. Endpoints were measured after 7 days of treatment. Primary endpoint was a reduction of at least one NYHA class. Secondary endpoints were changes in 6-min walk distance (6-MWD) compared with baseline, either alone or in ...
Source: European Journal of Heart Failure Supplements - February 29, 2016 Category: Cardiology Authors: Jing, Z.-C., Wu, B.-X., Peng, J.-J., Li, X.-L., Pan, L., Zhao, S.-P., Li, D.-Y., Yu, Z.-X., Gong, J.-B., Zhao, Q.-Y., Cao, J.-N., Sheng, G.-T., Li, J., Li, B. X., Jiang, S., Liang, C., Salvi, E., Carubelli, V. Tags: Articles Source Type: research

Serum cystatin C level and coronary artery plaque characteristics: an optical coherence tomography study
In this study, the relationship between the serum cystatin C level and characteristics of coronary plaques is evaluated in patients with coronary artery disease. The study involved 137 lesions in 82 patients. Plaque vulnerability, rupture, fibrotic cap thickness, microchannel, and calcified nodules were evaluated by optical coherence tomography. Cystatin C levels in acute coronary syndrome (ACS) patients and in non-ACS patients were 1.160 ± 0.595 and 0.973 ± 0.158 mg/L, respectively (P = 0.046). The cystatin C levels were not different between patients with and without ruptured plaques (P = 0.396), or between...
Source: European Journal of Heart Failure Supplements - February 29, 2016 Category: Cardiology Authors: Jin, Q., Chen, Y., Qian, G., Tian, F., Guo, J., Jing, J. Tags: Articles Source Type: research

Effects of levosimendan on calcium transient in norepinephrine-cultured neonatal rat ventricular myocytes
This study aimed to explore the changes in calcium transient in the development of heart failure and the effects of levosimendan (LeV) on intracellular calcium dynamics. Cultured neonatal rat ventricular myocytes were divided into four groups: normal, norepinephrine (NE) only (10 µmol/L), NE + LeV1 (0.1 µmol/L), and NE + LeV2 (1 µmol/L). The calcium transients of the myocytes loaded with Fluo-3/AM were observed using a laser scanning confocal microscope. Compared with the control group, the calcium wave in the NE group dispersed, propagated slowly, and exhibited dyssynchrony of Ca2+ release. Norepinephrin...
Source: European Journal of Heart Failure Supplements - February 29, 2016 Category: Cardiology Authors: Yang, Y.-q., Cao, J.-l., Zou, H.-y.-y., Han, Z.-l., Sun, H.-w., Hou, M.-H., Chen, M.-l., Kong, X.-q., Lu, X.-z. Tags: Articles Source Type: research

Effect of Shen-yuan on haemodynamic and anti-inflammatory factors in a porcine model of acute myocardial infarction
This study aimed to investigate whether the cardioprotective effects from Shen-yuan are due to regulation of haemodynamics and inflammation in a porcine model of acute MI. Myocardial infarction was induced by left anterior descending coronary artery ligation. Low, moderate, and high doses of Shen-yuan treatment were started 1 week before MI and continued for 2 weeks after MI. Whole blood viscosity at 15 s–1 and platelet aggregation rate were significantly increased in the MI group, but were markedly attenuated by high doses of Shen-yuan. A moderate dose of Shen-yuan also restored decreased values of the peak rise of ...
Source: European Journal of Heart Failure Supplements - February 29, 2016 Category: Cardiology Authors: Liang, W.-Y., Liu, M.-L., Feng, X.-R., Zhang, Z.-L., Zhu, X.-Y., Li, Y.-J., Liu, A., Yin, H.-J. Tags: Articles Source Type: research

A survey of national cardiology workforce in China
Cardiologists provided specialized care for patients with various cardiac conditions. The qualification system of subspecialty as cardiologist is well established in developed countries. However, there is no standardized national training programmes and common board certification for cardiovascular professionals in China. We launched a survey of national cardiology workforce to assess general characteristics of cardiovascular care providers in China. This survey includes licensed physicians who are currently working as cardiovascular care givers in tertiary or secondary hospitals in mainland China (Taiwan, Hongkong, and Ma...
Source: European Journal of Heart Failure Supplements - February 29, 2016 Category: Cardiology Authors: Gong, Y., Huo, Y., on behalf of Chinese College of Cardiovascular Physicians (CCCP) Tags: Articles Source Type: research

Ivabradine in practice
Ivabradine is an innovation in the cardiovascular fraternity with specific heart rate-lowering property, which expresses selective action on pacemaker activity in the sinoatrial node of the heart, resulting into important clinical benefits for improvement in coronary perfusion and pump efficiency. Ivabradine demonstrated substantial antianginal and anti-ischemic efficacy, improvement in exercise capacity and in quality of life in monotherapy or in combination with beta-blockers. The analysis of pooled data from ivabradine angina development programme assessing the antianginal efficacy of ivabradine across several different...
Source: European Journal of Heart Failure Supplements - December 16, 2015 Category: Cardiology Authors: Pinto, F. J. Tags: Articles Source Type: research

Prognostic and symptomatic benefits with ivabradine: lessons from the SHIFT trial
Ivabradine, a funny current (If) inhibitor, has been developed for symptomatic therapy of angina and in chronic heart failure (CHF) with low ejection fraction. A large outcome trial, SHIFT (Systolic Heart Failure Treatment with the If inhibitor ivabradine trial), was conducted in patients with EF ≤ 35% in sinus rhythm and increased heart rate ≥70 b.p.m. It demonstrated that the addition of this new compound to the best possible contemporary therapy, including beta-blockers, was associated with a 18% relative risk reduction in the occurrence of cardiovascular mortality or hospitalization for worsening heart failure (H...
Source: European Journal of Heart Failure Supplements - December 16, 2015 Category: Cardiology Authors: Komajda, M. Tags: Articles Source Type: research